Multi-Omics Based Drug Discovery and Development
October 1 - 2, 2025 - CA USHanson Wade
info@hansonwade.com
Phone:+1 617 455 4188
With advances in computing infrastructure and omics technologies within the market, biopharma leaders are increasingly adopting multi-omics within their workflows to accelerate drug discovery and development. In parallel, technology providers are expanding their multi-omics toolkits, with Illumina announcing a new suite of technologies and Element Biosciences raising $277M to develop differentiated products. The Inaugural Multi-Omics Based Drug Discovery and Development Summit 2025 has been positioned as the premier event for industry leaders to discuss the optimum applications of multi-omics in projects from early discovery to reverse translation, across diverse therapeutic areas including Oncology, Immunology, and Neuroscience. Join 60+ leaders in Computational Biology, Biomarker Discovery, Translational Research, and Pathology to uncover case studies on the use of harmonized omics technologies to de-risk clinical trials, inform patient stratification, identify biomarkers and novel targets and evaluate therapeutic response. Ensure your company effectively adopts and applies multi-omic technologies to holistically understand disease biology and accelerate the development of precise small molecule and biologic drugs. Time: 8:30 AM - 5:00 PM